国家发改委公布2013年医药产业各项数据

下载PDF

导出

摘要国家发改委近日公布2013年医药产业各项数据，表明2013年医药产业克服了欧美经济持续低迷等不利影响，产业主营业务收入、对外贸易总额、实现利润总额继续保持稳定增长，总体呈现平稳发展态势。

作者摘自丁香园

机构地区摘自丁香园

出处《上海医药》 CAS 2014年第5期41-41,共1页 Shanghai Medical & Pharmaceutical Journal

关键词国家发改委医药产业数业务收入对外贸易

参考文献100

1Akinbami L. Asthma prevalence, health care use andmortality: United States, 2005-2009 [J]. Nat Health Stat Rep,2011,12(32): 1-14.
2Frew AJ. Anti-IgE and asthma [J]. Ann Allergy AsthmaImmunol, 2003, 91(2): 154-159.
3Bang LM, Plosker GL. Spotlight on omalizumab in allergicasthma [J]. Biol Drugs, 2004, 18(6): 415-418.
4Rosenwasser LJ, Busse WW, Lizambri RG, et al. Allergicasthma and an anti-CD23 mAb (IDEC2152): results of aphase I,single-dose, dose-scalating clinical trial [J]. J AllergyClin Immunol, 2003, 112(3): 563-570.
5Omalizumab: anti-IgE monoclonal antibody E25, E25,humanized anti-IgE MAb, IGE025, monoclonal antibodyE25, Olizumab, Xolair, rhuMAb-E25 [J]. Biol Drugs, 2002,16(5): 380-386.
6Rosenwasser LJ. Mechanisms of IgE inflammation [J]. CurrAllergy Asthma Rep, 2011, 11(2): 178-183.
7Genentech Inc. Omalizumab (Xolair?): full prescribinginformation [EB/OL]. [2008-06-02]. http://www.gene.com/gene/products/information/immunological/xolair/insert. jsp.
8Gould HJ, Sutton BJ. IgE in allergy and asthma today [J]. NatRev Immunol, 2008,8(3): 205-217.
9MacGlashan DW, Bochner BS, Adelman DC, et al. Downregulation of FcsR I expression on human basophils duringin vivo treatment of atopic patients with anti-IgE antibody [J].J Immunol, 1997, 158(3): 1438-1445.
10Lee JJ, Dimina D, Macias MP, et al. Defining a link withasthma in mice congenitally deficient in eosinophils [J].Science, 2004,305(5691): 1773-1776.

上海医药

2014年第5期

内容加载中请稍等...